Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking a rare eye cancer pave the way for new treatments?

NCT ID NCT04588662

Knowledge-focused Sponsor: Columbia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study follows people diagnosed with uveal melanoma, a rare eye cancer, over time to document the disease's natural course. Researchers will collect data on how the cancer progresses, including survival rates and whether it spreads. The goal is to build a detailed registry that can inform and support the development of new therapies for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could provide crucial data to guide the development of new treatments for uveal melanoma, a rare eye cancer.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test any new therapy. Its value depends on long-term patient participation and data completeness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

122 people

The number who actually took part.

Started

May 2021

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Diagnosis of uveal melanoma * Male/Female over the age of 18 years of age

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Diagnosis of uveal melanoma * Ability to provide written informed consent for participation in the prospective registry OR an institutional waiver by the IRB/ethics committee for retrospective data collection without written informed consent Exclusion Criteria \*None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uveal melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uveal melanoma

Contacts and locations

Locations

  • Chatswood Eye Specialists

    Chatswood, Australia

  • Clatterbridge Cancer Centre

    Birkenhead, United Kingdom

  • Dr. Conway Private Rooms

    Sydney, Australia

  • Erlangen

    Erlangen, Germany

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Mount Vernon Cancer Centre

    Northwood, United Kingdom

  • Pennington Eye Clinic

    North Adelaide, Australia

  • Perth Retina

    Subiaco, Australia

  • Princess Margaret Cancer Center

    Toronto, Canada

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Victorian Eve and Ear Hospital

    East Melbourne, Australia

  • Sheffield

    Sheffield, United Kingdom

  • St. Vincent's Hospital

    Sydney, Australia

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • Western Eye Specialists

    Maribyrnong, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.